Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 10
Submit an article Journal homepage
1,673
Views
13
CrossRef citations to date
0
Altmetric
Neurology

Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a

Melissa A. FrascoPrecision Health Economics, Los Angeles, CA, USA; Correspondence[email protected]
,
Tiffany ShihPrecision Health Economics, Los Angeles, CA, USA;
,
Devin IncertiPrecision Health Economics, Los Angeles, CA, USA;
,
Oliver Diaz EspinosaPrecision Health Economics, Los Angeles, CA, USA;
,
Diana K. VaniaPrecision Health Economics, Los Angeles, CA, USA;
&
Nina ThomasGenentech, Inc., South San Francisco, CA, USA
Pages 1074-1082 | Received 22 May 2017, Accepted 15 Jul 2017, Published online: 04 Aug 2017

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter & Ivo Abraham. (2023) The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Pharmacoeconomics & Outcomes Research 23:3, pages 317-325.
Read now
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now

Articles from other publishers (11)

Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P Patel, François Blanchette, Nicholas Adlard, Umakanth Vudumula, Kapil Gudala, Nikkita Dutta, Daniel Grima, Soukaïna Mouallif & Fatine Farhane. (2023) Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. Journal of Comparative Effectiveness Research 12:9.
Crossref
B. Rodríguez-Sánchez, S. Daugbjerg, L. M. Peña-Longobardo, J. Oliva-Moreno, I. Aranda-Reneo, A. Cicchetti & J. López-Bastida. (2022) Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease. The European Journal of Health Economics 24:2, pages 247-277.
Crossref
Y. Seitaridou, M. Dimitrova, T. Chamova, M. Kamusheva & P. Panayotov. (2022) Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review. Acta Medica Bulgarica 49:4, pages 69-80.
Crossref
Dominik Koeditz, Jürgen Frensch, Martin Bierbaum, Nils-Henning Ness, Benjamin Ettle & Tjalf Ziemssen. (2022) Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland. Nervenheilkunde 41:07/08, pages 502-508.
Crossref
Dominik Koeditz, Juergen Frensch, Martin Bierbaum, Nils-Henning Ness, Benjamin Ettle, Umakanth Vudumula, Kapil Gudala, Nicholas Adlard, Santosh Tiwari & Tjalf Ziemssen. (2022) Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. Multiple Sclerosis Journal - Experimental, Translational and Clinical 8:1, pages 205521732210857.
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
S. Simeonova & R. Nikolova. (2021) Significance of the Dominant Psychological and Physiological Aspects of the Occupational Stress Models. Acta Medica Bulgarica 48:4, pages 33-42.
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Lisa Batcheller & David Baker. (2019) Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. Journal of the Neurological Sciences 404, pages 19-28.
Crossref
Viktor Chirikov, Ingrid Ma, Namita Joshi, Dipen Patel, Alden Smith, Cindy Giambrone, Noelle Cornelio & Lobat Hashemi. (2019) Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. Value in Health 22:2, pages 168-176.
Crossref
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.